Compare · AXGN vs PRKS
AXGN vs PRKS
Side-by-side comparison of Axogen Inc. (AXGN) and United Parks & Resorts Inc. (PRKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and PRKS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- PRKS is the larger of the two at $2.16B, about the same size as AXGN ($2.12B).
- AXGN has been more active in the news (16 items in the past 4 weeks vs 12 for PRKS).
- Both have 8 recent analyst ratings on file.
- Company
- Axogen Inc.
- United Parks & Resorts Inc.
- Price
- -
- -
- Market cap
- $2.12B
- $2.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 16
- 12
- Recent ratings
- 8
- 8
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Latest AXGN
- Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
- SEC Form 4 filed by Director Burke William P. Mr.
- SEC Form 4 filed by Director Tyndall Joseph A.
- SEC Form 4 filed by Director Levine Alan M
- SEC Form 4 filed by Director Johnson John
- SEC Form 4 filed by Director Thomas Paul
- SEC Form 4 filed by Director Wendell Amy Mcbride
- SEC Form 4 filed by Director Weiler Kathy Johnson
- Axogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Levine Alan M converted options into 14,150 shares, increasing direct ownership by 39% to 50,893 units (SEC Form 4)
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Northcoast initiated coverage on United Parks & Resorts Inc.
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 1,821 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 1,821 shares (SEC Form 4)
- Director Chambers James P. was granted 1,098 shares, increasing direct ownership by 2% to 65,558 units (SEC Form 4)
- Director Gray William was granted 1,258 shares, increasing direct ownership by 2% to 76,721 units (SEC Form 4)
- Director Hartnett Timothy was granted 1,821 shares, increasing direct ownership by 2% to 81,378 units (SEC Form 4)
- Director Lipman Nathaniel was granted 207 shares, increasing direct ownership by 1% to 20,316 units (SEC Form 4)
- Director Schaefer Kimberly was granted 415 shares, increasing direct ownership by 0.98% to 42,740 units (SEC Form 4)
- Director Narang Neha Jogani was granted 830 shares, increasing direct ownership by 1% to 57,376 units (SEC Form 4)